| No |
Treatment |
Sub-G1(%) |
G0/G1 (%) |
S (%) |
G2/M (%) |
| 1 |
T47D cell as control |
3,04 |
43,83 |
25,60 |
30,83 |
| 2 |
12,25 μg/mL of SA2014 |
3,99 |
47,51 |
23,20 |
29,44 |
| 3 |
31,25 μg/mL of SA2014 |
5,87 |
30,53 |
18,90 |
50,50 |
| 4 |
5 μg/mL of doxorubicin |
5,35 |
44,07 |
25 |
30,87 |
| 5 |
12,25 μg/ml of doxorubicin |
6,60 |
42,71 |
26,30 |
30,80 |
| 6 |
Combination of 12,25 μg/mL of SA2014 and 5 μg/mL of doxorubicin |
5,75 |
43,14 |
19,90 |
36,89 |
|
| Table 1: 1,4,9-triazatricyclo[7,3,1,0]trideca-3,5(13),10-trien-8-ol(SA2014) test
against T47D cell cycle. |
